Study for Inoperable Non-Metastatic Pancreatic CA (Stage IVA) With Neoadjuvant GTX, and Radiation With Gemzar
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether an experimental drug combination consisting
of Gemzar®, Taxotere®, and Xeloda®, (called GTX) when followed by radiation therapy plus
low-dose Gemzar, is safe and effective in treating advanced pancreatic cancer and to study
and enhance the utility of PET scans in the evaluation of patients with pancreatic cancer.